Welcome to our dedicated page for Opgen news (Ticker: OPGN), a resource for investors and traders seeking the latest updates and insights on Opgen stock.
OpGen, Inc. (NASDAQ: OPGN) regularly issues news and regulatory updates that describe its activities in precision medicine, molecular diagnostics, and bioinformatics for infectious disease and antimicrobial resistance. This news page aggregates those disclosures so readers can review how the company presents its business focus, collaborations, financings, and operational changes over time.
Company announcements have covered topics such as research and development collaborations involving antimicrobial resistance panels and genomic surveillance, feature releases for the AREScloud platform, and work related to the Unyvero systems and ARES Technology Platform. OpGen’s releases also discuss financial performance, cash management initiatives, and its own statements about substantial doubt regarding its ability to continue as a going concern, along with potential strategic alternatives it is considering.
Investors and observers can also find information here on equity and financing transactions, including preferred stock financings, warrant inducement agreements, and a securities purchase agreement that allows OpGen to sell common stock to an investor over time. Additional news items describe insolvency proceedings of subsidiaries Curetis GmbH and Ares Genetics GmbH, the sale of their assets by insolvency trustees, and agreements to transfer commercial customer contracts and installed Unyvero systems.
Corporate governance and management changes are another recurring theme in OpGen’s news, including appointments and resignations of directors and executive officers and a 1‑for‑10 reverse stock split intended, according to the company, to support compliance with Nasdaq’s minimum bid price requirement. This page allows readers to follow these developments through the company’s own published statements.
OpGen announced significant clinical results from its Unyvero Hospitalized Pneumonia (HPN) panel, demonstrating a 45.1% reduction in inappropriate antibiotic therapy and an average therapy duration decrease of 39 hours. The study involving 208 patients showed a threefold increase in avoiding inappropriate therapy for those diagnosed using Unyvero. Results presented at the European Respiratory Society conference reflect the tool's effectiveness in managing pneumonia cases at risk for Gram-negative bacteria, underscoring its potential in antibiotic stewardship.
OpGen reported a total revenue of approximately $0.8 million for Q2 2021, a 32% decline compared to Q2 2020's $1.2 million. This decrease is attributed to the exit from the FISH business and the conclusion of prior R&D collaborations. Operating expenses decreased to $7.0 million from $7.7 million year-over-year. Despite net losses of $7.1 million ($0.19 per share), cash reserves improved significantly to $31.2 million, up from $13.4 million at the end of 2020. Key milestones include the assembly of Unyvero A30 RQ analyzers and progress in FDA submissions.
OpGen, Inc. (Nasdaq: OPGN) announced it will withdraw Proposal 2 from its Definitive Proxy Statement regarding an increase in authorized shares, leading to the cancellation of the reconvened Annual Meeting set for August 5, 2021. This decision follows the approval of all other proposals during the Annual Meeting on June 9, 2021. The company is exploring alternatives for financing its future growth. OpGen focuses on precision medicine through molecular diagnostics and aims to improve treatment outcomes for infectious diseases.
OpGen, Inc. (NASDAQ: OPGN) will report its Q2 2021 financial results and provide a business update on August 12, 2021, after U.S. market close. The management team will host a live conference call at 4:30 p.m. ET to discuss these results and business activities. Interested parties may join via the U.S. or International dial-in numbers provided or through a webcast link. A replay will be accessible until August 26, 2021. OpGen focuses on precision medicine and developing molecular diagnostics for infectious diseases to improve patient outcomes.
OpGen has announced the completion of assembly for 10 pre-series Unyvero A30 RQ analyzers by its subsidiary Curetis. This marks a significant milestone as these instruments will enter final verification and validation testing. The A30 RQ platform aims to provide rapid, multiplexed testing from various clinical specimens, yielding results in as little as 30 minutes. Future product developments are being evaluated, and the platform is open for licensing opportunities, enhancing OpGen's strategic partnerships.
OpGen, Inc. has adjourned its annual stockholders meeting to allow additional time for votes on Proposal 2, which seeks to increase the authorized shares of common stock. The meeting will resume on August 5, 2021, at 10:00 AM ET. CEO Oliver Schacht emphasized the importance of this proposal for the company's future and potential financing needs, noting a strong cash position of $39.4 million as of Q1 2021. However, at least 66.67% of shares must vote in favor for it to pass. The Board is also exploring alternative financing options.
OpGen, Inc. (Nasdaq: OPGN) shared promising prospective clinical data on its Unyvero LRT BAL panel during a recent webinar. The panel demonstrated its ability to adjust antimicrobial therapy in 53% of ICU patients, providing results 21 hours faster than conventional tests. With 99.2% concordance for organism targets and significant detection of pneumonia-causing bacteria, the panel reduces unnecessary antibiotic use and associated adverse effects. Additionally, the Acuitas AMR Gene Panel showcased potential in infection control at the World Microbe Forum, further underscoring OpGen's commitment to combating antimicrobial resistance.
OpGen, Inc. (Nasdaq: OPGN) announced promising preliminary data from Ares Genetics’ multicenter validation of long-read nanopore sequencing. The results showed 100% accuracy in pathogen identification, with up to 97% accuracy for antimicrobial resistance (AMR) markers. Ares Genetics aims to enhance AMR surveillance through cost-effective and efficient sequencing technologies, particularly in low to mid-income countries, where AMR outbreaks are a rising concern. The AREScloud software will facilitate data analysis and interpretation, supporting clinical adoption and accurate diagnostics.
OpGen, Inc. (Nasdaq: OPGN) announced the adjournment of its 2021 Annual Stockholders Meeting specifically for Proposal 2, which seeks to increase the company's authorized shares from 60 million to 110 million. The proposal received favorable initial votes, with over two-thirds in support from approximately 43% of voting shareholders. The meeting will resume on July 7, 2021. CEO Oliver Schacht emphasized the necessity of this proposal for the company's growth and flexibility, especially in managing long-term debt and raising capital. OpGen held $39.4 million in cash at Q1-end 2021.
OpGen announced its subsidiary Ares Genetics is developing a culture-free genomic assay for antimicrobial resistance (AMR) surveillance. The Ares universal pathogenome assay (ARESupa) aims to surpass limitations of current methods by using over 8,000 genetic markers. Preliminary studies indicate sensitivity rates between 94% and 100% for detecting AMR markers. A paid early access program has signed five public health organizations. This initiative supports OpGen's commercial strategies in pathogen and AMR surveillance, showcasing potential for improved diagnostic capabilities.